BOSTON - A pension plan claims Astrazeneca, Ranbaxy, Teva and others conspired to delay introduction of a generic form of Nexium for up to 6 years, in a federal antitrust class action.
Categories / Uncategorized
Subscribe to Closing Arguments
Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.
Additional Reads
-
FTC vs Facebook November 27, 2023 -
-
-
‘Stop Woke’ subpoenas October 30, 2023